Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053774 · ClinicalTrials.gov registry record · Phase 2
Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain
A Phase 2 study of Pain, Acute, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07053774: Recruiting Phase 2 study of Pain, Acute, sponsored by Wake Forest University Health Sciences.
NCT07053774 is a Phase 2 study of Pain, Acute that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 24 participants, below the 101-participant average among 31 other Pain, Acute trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053774, a Phase 2 study of Pain, Acute, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research study is to find out how well oxytocin works to reduce pain. Oxytocin will be given intravenously (IV) and as a nasal spray. The study team also hopes to find out if the participants age, weight, or sex effects how well the study drug works. Participants will be exposed to a heater on the skin at a training visit and rate how much pain different temperatures cause. On two separate visits, participants will use a nasal spray and get an IV infusion. After the IV and nasal spray, participants will rate the pain of the same skin heating temperature at various time points for 4 hours.
Primary Outcome
Change in verbal pain scale score. Range is 0-10. 0 is equivalent to no pain and 10 is equivalent to the worst pain imaginable.
Conditions Studied
Interventions
- DRUG Intravenous oxytocin
- DRUG Intravenous placebo
- DRUG Intranasal oxytocin
- DRUG Intranasal placebo
Study Locations (1)
North Carolina
- Atrium Health Wake Forest Baptist - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2026-06-28 |
| Phase | Phase 2 |
What NCT07053774 shows while recruiting
NCT07053774 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 101-participant average among 31 other Pain, Acute trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Pain, Acute appearing as the primary indexed condition, and to 4 interventions - of which Intravenous oxytocin is the first listed.
NCT07053774 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07053774 about?
NCT07053774 is a clinical study titled "Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain". The goal of this research study is to find out how well oxytocin works to reduce pain. Oxytocin will be given intravenously (IV) and as a nasal spray. The study team also hopes to find out if the participants age, weight, or sex effects how well the study drug works. Participants will be exposed to...
What is the current status of trial NCT07053774?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-11-05. Estimated completion is 2026-06-28.
What conditions does trial NCT07053774 study?
This clinical trial studies the following conditions: Pain, Acute.
What interventions are being tested in trial NCT07053774?
The interventions under investigation include: Intravenous oxytocin (DRUG), Intravenous placebo (DRUG), Intranasal oxytocin (DRUG), Intranasal placebo (DRUG).
Who is sponsoring clinical trial NCT07053774?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053774 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07053774's enrollment target sits among peer trials
24 30th of 31 higher than 1 of 31 other Pain, Acute trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Valacyclovir in Pain Management of Acute Apical Abscesses
RECRUITING · Phase 2
-
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
ACTIVE NOT RECRUITING · Phase 2
-
Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain
COMPLETED · Phase 2
-
RTMS for Treatment of Pain and Craving
COMPLETED · Phase 2
-
TENS Unit for Analgesia During IUD Insertion
RECRUITING · NA
-
Variability in Analgesic Response to Ibuprofen
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI